Oriol Bestard M.
- Country
- Spain
- Department
- Nephrology and Transplantation
Research Overview
- Frexalimab Versus Tacrolimus for Prevention of Kidney Graft Rejection in Adult Kidney Transplant Recipients
- Phase IV Study of Maribavir for Reduction of Epstein-Barr Virus Replication in Young Adult Kidney Transplant Recipients
- Evaluation of Tegoprubart Versus Tacrolimus in Prophylaxis of Renal Allograft Rejection in Kidney Transplant Recipients
Data & Insights
Has run more than one trial at 30 of 71 partner sites.
Specializations
Kidney Transplantation Optimization
The investigator specializes in developing advanced approaches for kidney transplant optimization, particularly focusing on immunosuppressive therapy management and graft survival improvement.
- Immunological Risk Assessment
- Biomarker-Based Treatment Strategies
- Living Donor Transplantation
Their work encompasses innovative protocols for personalizing immunosuppressive regimens based on patient-specific factors.
Transplant Rejection Management
The investigator's expertise extends to preventing and treating antibody-mediated rejection in transplant recipients, with particular attention to highly sensitized patients.
- Novel Therapeutic Approaches
- Antibody Removal Techniques
- Long-term Graft Protection
Their research addresses critical challenges in managing complex transplant cases and improving outcomes for sensitized recipients.
Transplant Immunology
The investigator focuses on understanding and modulating transplant immunity, including research into viral infection prevention and immune system adaptation post-transplantation.
- Adaptive Immunity Studies
- Viral Infection Prevention
- Immune Response Monitoring
Their work includes developing strategies to protect against post-transplant complications while maintaining optimal immunological balance.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.